List of works - Signe Sørensen Torekov

A Functional Amino Acid Substitution in the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Gene Is Associated With Lower Bone Mineral Density and Increased Fracture Risk

article

Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass

scientific article published on 30 August 2019

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

scientific article

Association between Neuromedin U Gene Variants and Overweight and Obesity

article

Atrial Natriuretic Peptide in the High Normal Range Is Associated With Lower Prevalence of Insulin Resistance

scientific article published on 27 January 2016

Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists

scientific article published on 01 August 2019

Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system

scientific article published on 25 April 2017

Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses

scientific article published on 16 March 2018

Correction to: Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists

scientific article published on 01 July 2019

Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus

scientific article published on 10 December 2013

Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes

scientific article published in July 2011

Effects of vegan diets on cardiometabolic health: A systematic review and meta‐analysis of randomized controlled trials

scientific article published on 7 June 2022

Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids

scientific article published on 5 January 2018

Evidence of an association between the Arg72 allele of the peptide YY and increased risk of type 2 diabetes.

scientific article published in July 2005

Family and population-based studies of variation within the ghrelin receptor locus in relation to measures of obesity

scientific article

GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women

scientific article published on 4 June 2015

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report

scientific article published on 21 April 2020

GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study

article

Gain-of-function mutation in the voltage-gated potassium channel gene KCNQ1 and glucose-stimulated hypoinsulinemia - case report

scientific article published on 13 March 2020

Genetic analysis of the estrogen-related receptor α and studies of association with obesity and type 2 diabetes

article

Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?

scientific article published on 10 September 2017

Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL

scientific article published on 01 August 2018

Glucose ingestion causes cardiac repolarization disturbances in type 1 long QT syndrome patients and healthy subjects.

scientific article published on 8 April 2017

Glucose-Dependent Insulinotropic Polypeptide Is Associated With Lower Low-Density Lipoprotein But Unhealthy Fat Distribution, Independent of Insulin: The ADDITION-PRO Study

scientific article published on 27 October 2015

Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

scientific article published on 05 October 2019

Habitual physical activity is associated with lower fasting and greater glucose-induced GLP-1 response in men

scientific article published on 01 December 2019

Health care professionals from developing countries report educational benefits after an online diabetes course

scientific article

Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1.

scientific article published on 7 August 2011

Instrumentalization of Eating Improves Weight Loss Maintenance in Obesity

scientific article published on 6 December 2017

Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation

scientific article published on 8 August 2016

KCNQ1 long QT syndrome patients have hyperinsulinemia and symptomatic hypoglycemia

scientific article

Large-scale studies of the HphI insulin gene variable-number-of-tandem-repeats polymorphism in relation to Type 2 diabetes mellitus and insulin release

scientific article

Liraglutide for Type 2 diabetes and obesity: a 2015 update

scientific article published on July 2015

Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation

scientific article published on 17 October 2007

Major rapid weight loss induces changes in cardiac repolarization

scientific article published on 10 February 2016

No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post-hoc analysis from the randomized controlled PRE-D trial

scientific article published on 04 November 2020

Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential ⬇️

scientific article published on March 15, 2011

Patients With Long-QT Syndrome Caused by Impaired hERG-Encoded Kv11.1 Potassium Channel Have Exaggerated Endocrine Pancreatic and Incretin Function Associated With Reactive Hypoglycemia

scientific article

Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist

scientific article published on 31 May 2018

Plasma Proteome Profiling Reveals Dynamics of Inflammatory and Lipid Homeostasis Markers after Roux-En-Y Gastric Bypass Surgery

scientific article published on 05 December 2018

Proteomics reveals the effects of sustained weight loss on the human plasma proteome

scientific article

Protocol for a single-centre, parallel-group, randomised, controlled, superiority trial on the effects of time-restricted eating on body weight, behaviour and metabolism in individuals at high risk of type 2 diabetes: the REStricted Eating Time (RES

scientific article published on 26 August 2020

Response to Comment on Færch et al. GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. Diabetes 2015;64:2513–2525

Role of fasting duration and weekday in incretin and glucose regulation

scientific article published on 01 March 2020

Searching for the physiological role of glucose-dependent insulinotropic polypeptide

scientific article

Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36.

scientific article

Therapies for inter-relating diabetes and obesity - GLP-1 and obesity

scientific article published on 26 September 2014

Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.

scientific article

Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB.

scientific article published on 21 November 2017

Variants in the 5′ region of the neuropeptide Y receptor Y2 gene (NPY2R) are associated with obesity in 5,971 white subjects

article

List of works by Signe Sørensen Torekov

A Functional Amino Acid Substitution in the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Gene Is Associated With Lower Bone Mineral Density and Increased Fracture Risk

Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

Association between Neuromedin U Gene Variants and Overweight and Obesity

Atrial Natriuretic Peptide in the High Normal Range Is Associated With Lower Prevalence of Insulin Resistance

Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists

Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system

Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses

Correction to: Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists

Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus

Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes

Effects of vegan diets on cardiometabolic health: A systematic review and meta‐analysis of randomized controlled trials

Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids

Evidence of an association between the Arg72 allele of the peptide YY and increased risk of type 2 diabetes.

Family and population-based studies of variation within the ghrelin receptor locus in relation to measures of obesity

GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report

GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study

Gain-of-function mutation in the voltage-gated potassium channel gene KCNQ1 and glucose-stimulated hypoinsulinemia - case report

Genetic analysis of the estrogen-related receptor α and studies of association with obesity and type 2 diabetes

Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?

Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL

Glucose ingestion causes cardiac repolarization disturbances in type 1 long QT syndrome patients and healthy subjects.

Glucose-Dependent Insulinotropic Polypeptide Is Associated With Lower Low-Density Lipoprotein But Unhealthy Fat Distribution, Independent of Insulin: The ADDITION-PRO Study

Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

Habitual physical activity is associated with lower fasting and greater glucose-induced GLP-1 response in men

Health care professionals from developing countries report educational benefits after an online diabetes course

Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1.

Instrumentalization of Eating Improves Weight Loss Maintenance in Obesity

Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation

KCNQ1 long QT syndrome patients have hyperinsulinemia and symptomatic hypoglycemia

Large-scale studies of the HphI insulin gene variable-number-of-tandem-repeats polymorphism in relation to Type 2 diabetes mellitus and insulin release

Liraglutide for Type 2 diabetes and obesity: a 2015 update

Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation

Major rapid weight loss induces changes in cardiac repolarization

No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post-hoc analysis from the randomized controlled PRE-D trial

Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential ⬇️

Patients With Long-QT Syndrome Caused by Impaired hERG-Encoded Kv11.1 Potassium Channel Have Exaggerated Endocrine Pancreatic and Incretin Function Associated With Reactive Hypoglycemia

Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist

Plasma Proteome Profiling Reveals Dynamics of Inflammatory and Lipid Homeostasis Markers after Roux-En-Y Gastric Bypass Surgery

Proteomics reveals the effects of sustained weight loss on the human plasma proteome

Protocol for a single-centre, parallel-group, randomised, controlled, superiority trial on the effects of time-restricted eating on body weight, behaviour and metabolism in individuals at high risk of type 2 diabetes: the REStricted Eating Time (RES

Response to Comment on Færch et al. GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. Diabetes 2015;64:2513–2525

Role of fasting duration and weekday in incretin and glucose regulation

Searching for the physiological role of glucose-dependent insulinotropic polypeptide

Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36.

Therapies for inter-relating diabetes and obesity - GLP-1 and obesity

Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.

Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB.

Variants in the 5′ region of the neuropeptide Y receptor Y2 gene (NPY2R) are associated with obesity in 5,971 white subjects

Weight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels